Can Athersys Inc (NASDAQ:ATHX)’s Tomorrow be Different? The Stock Had Increase in Shorts

November 10, 2018 - By Adrian Mccoy

Athersys, Inc. (NASDAQ:ATHX) Logo

Investors sentiment increased to 2.42 in Q2 2018. Its up 1.53, from 0.89 in 2018Q1. It improved, as 3 investors sold Athersys, Inc. shares while 16 reduced holdings. 15 funds opened positions while 31 raised stakes. 25.84 million shares or 11.94% more from 23.09 million shares in 2018Q1 were reported.
Moneta Grp Investment Advisors Ltd Co owns 1,133 shares or 0% of their US portfolio. State Street Corporation has 1.88M shares for 0% of their portfolio. West Oak Cap Limited accumulated 300 shares. Credit Suisse Ag invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). The California-based Wells Fargo & Mn has invested 0% in Athersys, Inc. (NASDAQ:ATHX). Alliancebernstein Limited Partnership owns 90,700 shares. Catawba Capital Mngmt Va holds 0% or 10,000 shares. State Board Of Administration Of Florida Retirement reported 16,400 shares. Manufacturers Life Insurance Co The accumulated 93,960 shares or 0% of the stock. Jefferies Grp Incorporated Ltd Llc invested in 15,100 shares or 0% of the stock. Ancora Limited Com invested 0% in Athersys, Inc. (NASDAQ:ATHX). 10,000 are held by Umb Comml Bank N A Mo. Natixis invested 0% of its portfolio in Athersys, Inc. (NASDAQ:ATHX). Tci Wealth holds 0.01% or 6,300 shares in its portfolio. Cambridge Incorporated owns 12,795 shares.

Since June 14, 2018, it had 0 insider buys, and 5 selling transactions for $216,786 activity. Harrington John J also sold $28,707 worth of Athersys, Inc. (NASDAQ:ATHX) on Thursday, September 13. The insider Campbell Laura K sold $57,986.

The stock of Athersys Inc (NASDAQ:ATHX) registered an increase of 0.19% in short interest. ATHX’s total short interest was 11.07M shares in November as published by FINRA. Its up 0.19% from 11.05M shares, reported previously. With 370,600 shares average volume, it will take short sellers 30 days to cover their ATHX’s short positions.

The stock decreased 2.09% or $0.04 during the last trading session, reaching $1.87. About 358,019 shares traded. Athersys, Inc. (NASDAQ:ATHX) has declined 3.52% since November 10, 2017 and is downtrending. It has underperformed by 19.14% the S&P500.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company has market cap of $259.15 million. The Company’s clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. It currently has negative earnings. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers.

More news for Athersys, Inc. (NASDAQ:ATHX) were recently published by: Globenewswire.com, which released: “Market Trends Toward New Normal in Crown, Athersys, CSX, Magellan Health, Spectrum Brands, and MGIC …” on October 29, 2018. Globenewswire.com‘s article titled: “Athersys Reports Third Quarter 2018 Results” and published on November 06, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>